Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SPRY | COURT-RULING | neutral | 3/10 | The court transferred ARS Pharmaceuticals' antitrust lawsuit against AptarGroup to the Southern District of New York und | Jul 19, 2026 |
| FDMT | PRESS-RELEASE | bullish | 6/10 | 4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing 78% | Jul 18, 2026 |
| GLUE | CLUSTER | neutral | 2/10 | President & CEO Markus Warmuth and COO Jennifer Champoux sold a combined $322K in open-market sales over two days, with | Jul 18, 2026 |
| CGON | CLUSTER | neutral | 2/10 | Two CG Oncology directors sold a combined $1.89M in stock over a 7-day window, with the bulk ($1.82M) sold by director J | Jul 18, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three UTHR insiders (CEO, EVP & General Counsel, and a Director) sold shares in a cluster from July 9-16, 2026. The CEO | Jul 18, 2026 |
| ONC | CLUSTER | bearish | 5/10 | CEO John Oyler sold ~$43.2M in open-market shares on July 16-17 after exercising options, while SVP/General Counsel Lee | Jul 18, 2026 |
| MPLT | CLUSTER | neutral | 2/10 | Two senior insiders at MapLight Therapeutics, the General Counsel and Chief Medical Officer, executed open-market sales | Jul 17, 2026 |
| MNKD | CLUSTER | neutral | 3/10 | Two insiders at MannKind Corp, the EVP General Counsel and a Director, sold a combined $311K in open-market shares on Ju | Jul 17, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders (CFO Mokari Atabak and Director James N. Wilson) sold a combined $2.59M in open-market | Jul 17, 2026 |
| IOVA | COURT-RULING | bearish | 5/10 | Iovance Biotherapeutics lost a summary judgment ruling in its insurance coverage dispute with Federal Insurance Company. | Jul 17, 2026 |
| IKT | 3 | bullish | 6/10 | RA Capital Healthcare Fund LP and affiliated entities (RA Capital Management, Peter Kolchinsky, Rajeev Shah) filed initi | Jul 17, 2026 |
| OGN | 8-K | neutral | 3/10 | Organon filed an 8-K supplementing its definitive proxy statement for the pending Sun Pharma merger to address a shareho | Jul 17, 2026 |
| CMND | 6-K | neutral | 2/10 | Clearmind Medicine issued a press release commending recent federal regulatory developments supporting psychedelic-based | Jul 17, 2026 |
| KPTI | 8-K | neutral | 3/10 | Karyopharm Therapeutics implemented a 2026 Leadership Cash Retention Program providing lump-sum cash awards totaling $3. | Jul 17, 2026 |
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced that updated data from its [212Pb]VMT-α-NET program for neuroendocrine tumors has bee | Jul 17, 2026 |
| ADTX | 8-K | neutral | 2/10 | Aditxt entered into Amendment No. 2 to its Note Purchase Agreement, allowing a new investor to join, cancelling one exis | Jul 17, 2026 |
| CMPX | PRESS-RELEASE | bullish | 6/10 | Compass Therapeutics announces that its Phase 2/3 COMPANION-002 trial of tovecimig + paclitaxel in advanced biliary trac | Jul 17, 2026 |
| RAPH | 8-K | neutral | 4/10 | Raphael Pharmaceutical Inc. filed an 8-K reporting the voluntary resignations of Chairman Ajay Kumar Dhadha (effective J | Jul 17, 2026 |
| VIVS | 8-K | bearish | 7/10 | VivoSim Labs raised ~$4M in a private placement via the sale of pre-funded warrants (4,705,883 shares at $0.001 exercise | Jul 17, 2026 |
| CNTN | 8-K | neutral | 2/10 | Canton Strategic Holdings filed an 8-K reporting results from its 2026 annual meeting of stockholders held on July 13, 2 | Jul 17, 2026 |
| CNTN | PRESS-RELEASE | neutral | 3/10 | Canton Strategic Holdings issued a Q2 2026 ecosystem report on the Canton Network, highlighting governance milestones an | Jul 17, 2026 |
| AMRX | PRESS-RELEASE | bullish | 6/10 | Amneal received FDA approval for additional strengths and vial presentations of iohexol injection, a generic version of | Jul 17, 2026 |
| PLYX | 8-K | neutral | 2/10 | Polaryx Therapeutics filed an 8-K setting the date for its 2026 Annual Meeting of Stockholders as September 10, 2026, to | Jul 17, 2026 |
| EVAX | 6-K | bullish | 7/10 | Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ES | Jul 17, 2026 |
| LSTA | 8-K | neutral | 3/10 | Lisata Therapeutics (LSTA) and Kuva Labs extended the Outside Date of their existing Merger Agreement from July 17, 2026 | Jul 17, 2026 |
| FBLG | EFFECT | bearish | 6/10 | The SEC declared effective FibroBiologics' S-1 registration statement (File No. 333-297353) on July 16, 2026, enabling t | Jul 17, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences adopted a new 2026 Omnibus Share Incentive Plan, authorizing up to 11,960,000 ordinary shares (5, | Jul 17, 2026 |
| SNY | 6-K | bullish | 6/10 | Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indica | Jul 17, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third- | Jul 17, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK announced the re-appointment of Deloitte LLP as its external auditor effective from the financial year ending Decemb | Jul 17, 2026 |